Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueNotes PayablesOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vistagen Therapeutics (VTGN) Accumulated Depreciation (2020)

Vistagen Therapeutics' Accumulated Depreciation history spans 3 years, with the latest figure at $1.0 million for Q1 2020.

  • For Q1 2020, Accumulated Depreciation changed N/A year-over-year to $1.0 million; the TTM value through Mar 2020 reached $1.0 million, changed N/A, while the annual FY2020 figure was $1.0 million, N/A changed from the prior year.
  • Accumulated Depreciation for Q1 2020 was $1.0 million at Vistagen Therapeutics, up from $711000.0 in the prior quarter.
  • Across five years, Accumulated Depreciation topped out at $1.0 million in Q1 2020 and bottomed at $711000.0 in Q1 2016.